^
Association details:
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
New
Title:

Heterogeneity of Genetic Changes Associated with Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancer

Excerpt:
ALK Mutations Confer Resistance to Crizotinib.
DOI:
https://doi.org/10.1097/JTO.0b013e318283dcc0
Evidence Level:
Resistant: D – Preclinical
New
Title:

The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer

Excerpt:
In Ba/F3 models, ceritinib was highly active against L1196M, G1269A, S1206Y...The initial interrogation of ceritinib resistant patient biopsies supports the notion that ceritinib is able to effectively suppress many crizotinib-resistance mutations…This suggests that predominant clones with the S1206Y and G1269A mutations were suppressed by ceritinib...
DOI:
10.1158/2159-8290.CD-13-0846